

February 27, 2023

Senju Pharmaceutical Co., Ltd.

Announcement of collaboration agreement with Alchemedicine, Inc.

Senju Pharmaceutical Co., Ltd. today announced that we have entered into a collaboration agreement with Alchemedicine, Inc. to conduct joint research. Under this agreement, Alchemedicine will discover and optimize drug candidate for one target of interest in Senju Pharmaceutical.

With a sense of mission to serve the eye health of people around the world and a development policy that places the highest priority on safety, we have always been ahead of the times as a pioneer in ophthalmic medicines and have been on a path of creativity. With a desire to develop even more original new products for the future, we aim to create and offer superior pharmaceuticals and services in the five sensory functions (eyesight, hearing, smell, taste and touch) through which people feel the joy of living.

Through this agreement, we will bring together Alchemedicine’s expertise in medicinal chemistry and our expertise in the field of ophthalmology to create drug candidate compounds for which there is a high unmet medical need.

[Contact details for inquiries]

Corporate Communication Department, Senju Pharmaceutical Co., Ltd.

3-1-9, Kawara-machi, Chuo-ku, Osaka 541-0048, Japan

Mail: cc@senju.co.jp

URL: <https://www.senju.co.jp>